JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Trajectories of forced vital capacity in patients with systemic sclerosis-associated interstitial lung disease

  • 0Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Oliver.Distler@usz.ch.
Arthritis Research & Therapy +

|

March 22, 2025

|

March 22, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Long-term nintedanib treatment slowed lung function decline in systemic sclerosis-associated interstitial lung disease (SSc-ILD). Switching from placebo to nintedanib also demonstrated a beneficial effect on forced vital capacity (FVC) progression in SSc-ILD patients.

Area Of Science

  • Pulmonology
  • Rheumatology
  • Clinical Pharmacology

Background

  • Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a progressive condition with significant morbidity.
  • Forced vital capacity (FVC) decline is a key indicator of disease progression and prognosis in SSc-ILD.
  • Nintedanib is an approved treatment for SSc-ILD, but long-term efficacy and the effect of switching from placebo require further assessment.

Purpose Of The Study

  • To evaluate the long-term effect of nintedanib on FVC decline in patients with SSc-ILD.
  • To assess the impact of switching from placebo to nintedanib on lung function trajectory.
  • To analyze FVC changes in patients continuing nintedanib versus those initiating it after placebo exposure.

Main Methods

  • Analysis of data from the SENSCIS and SENSCIS-ON clinical trials.
  • Assessment of FVC decline in patients receiving continuous nintedanib treatment.
  • Evaluation of FVC changes in patients switching from placebo to nintedanib.
  • Anchor measurements used: last on-treatment FVC in SENSCIS and baseline FVC in SENSCIS-ON.

Main Results

  • Patients on continuous nintedanib showed a mean FVC decline of -41.5 mL in SENSCIS and -58.3 mL in SENSCIS-ON over 52 weeks.
  • Patients switching from placebo to nintedanib had a mean FVC decline of -96.8 mL in SENSCIS (placebo) and -42.8 mL in SENSCIS-ON (nintedanib) over 52 weeks.
  • These results indicate a slower rate of FVC decline when patients receive nintedanib.

Conclusions

  • Nintedanib demonstrates sustained efficacy in slowing lung function decline in SSc-ILD over the long term.
  • Initiating nintedanib treatment, even after a period of placebo, can mitigate the progressive decline in FVC.
  • The findings support the long-term use of nintedanib for managing SSc-ILD and preserving lung function.

Keywords:

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology 01:20

2.7K

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

• Inhalation of Irritants: Inhaling irritants, especially cigarette smoke, are primary causes of inflammation in COPD. Other irritants can include...

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies 01:27

2.5K

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History

• Symptom Review: Chronic symptoms such as persistent cough, sputum production, shortness of breath (dyspnea), and episodes of exacerbation are...

Lung Capacity 01:47

48.9K

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.

There are four defined lung volume measures: tidal volume, inspiratory reserve volume, expiratory reserve volume, and residual volume.

Tidal volume is the amount of air inhaled and exhaled in a normal breath. Inspiratory...

COPD: Pathogenesis and Clinical Features 01:20

219

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Pulmonary Function Tests 01:25

282

Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...

Respiratory Volumes and Capacities I 01:26

796

Assessing the respiratory rate and rhythm for a complete minute is crucial for evaluating the breathing pattern. Even a minor increase in the patient's average respiratory rate, by as little as three to five breaths per minute, is an early and vital indicator of respiratory distress. Patients with a respiratory rate exceeding twenty-four breaths per minute require close monitoring to determine the physiological alterations. This careful observation is essential for prompt recognition and...